Evidence map›Paper›PMID 40047015›Full record

ArticleF1000Research2025

Recombinant expression of receptor binding domains of all eight subtypes of botulinum neurotoxin type A for generation of antitoxins with broad reactivity.

Nga Quynh Pham, Tam Trang Mai, Tran Bao Anh Dang, Ly Huong Tran, Quynh Mai Vu, Chien Trong Nguyen, Anh Thi Phuong Tran, Tran Nhat Minh Dang, Van Anh Tran, Thinh Huy Tran and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nga Quynh PhamSchool of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam.
Tam Trang MaiHigh School for the Gifted in Natural Sciences, Vietnam National University, Hanoi, 120558, Vietnam.
Tran Bao Anh DangHigh School for the Gifted in Natural Sciences, Vietnam National University, Hanoi, 120558, Vietnam.
Ly Huong TranSchool of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam.
Quynh Mai VuSchool of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam.
Chien Trong NguyenSchool of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam.
Anh Thi Phuong TranSchool of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam.
Tran Nhat Minh DangHanoi Medical University, Hanoi, 11521, Vietnam.
Van Anh TranHanoi Medical University, Hanoi, 11521, Vietnam.
Thinh Huy TranCenter for Gene and Protein Research, Hanoi Medical University, Hanoi, 11521, Vietnam.
Van Khanh TranCenter for Gene and Protein Research, Hanoi Medical University, Hanoi, 11521, Vietnam.
Hoa Quang LeSchool of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam.ORCID https://orcid.org/0000-0002-1853-7397

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Botulinum neurotoxin type A (BoNT/A) represents a major threat to global public health because of its most potent toxicity with the longest persistence. Several camelid single-domain antibodies (or VHHs) have been reported to exhibit high neutralizing activity against the receptor binding domain (H Methods: H Results: SDS-PAGE analysis and ELISA results with commercial polyclonal antibody demonstrated the H Conclusion: This study provided a resource to comprehensively identify antitoxins conferring broad protection against BoNT/A.

Indexed as

Botulinum Toxins, Type ASingle-Domain AntibodiesAnimalsAntibodies, NeutralizingEscherichia coliProtein DomainsRecombinant ProteinsAntibodies, NeutralizingBotulinum Toxins, Type ARecombinant ProteinsSingle-Domain Antibodiesantitoxinbotulinum neurotoxinsbotulismHCnanobodyneutralizationreceptor-binding domainrecombinant proteinsVHH

Identifiers

PMID40047015
PMCPMC11880751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.